DR LAL PATHLABS
|
DR LAL PATHLABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 30.13 | 58.28 | 42.85 | 28.65 | 41.37 |
| CEPS(Rs) | 40.08 | 37.93 | 30.30 | 23.47 | 27.50 |
| DPS(Rs) | 20.50 | 24.00 | 24.00 | 12.00 | 12.00 |
| Book NAV/Share(Rs) | 145.75 | 253.14 | 215.40 | 192.88 | 173.17 |
| Tax Rate(%) | 23.81 | 21.21 | 28.32 | 29.88 | 26.25 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 28.32 | 28.26 | 27.36 | 24.29 | 26.86 |
| EBIT Margin(%) | 25.04 | 26.29 | 24.02 | 18.91 | 24.20 |
| Pre Tax Margin(%) | 24.22 | 25.38 | 22.70 | 17.05 | 22.75 |
| PAT Margin (%) | 18.45 | 20.00 | 16.27 | 11.95 | 16.78 |
| Cash Profit Margin (%) | 24.31 | 25.76 | 22.72 | 19.40 | 21.96 |
| Performance Ratios | |||||
| ROA(%) | 17.92 | 19.53 | 15.23 | 10.36 | 17.77 |
| ROE(%) | 22.37 | 25.15 | 21.27 | 15.80 | 26.45 |
| ROCE(%) | 29.56 | 31.53 | 27.89 | 20.34 | 32.67 |
| Asset Turnover(x) | 0.97 | 0.98 | 0.94 | 0.87 | 1.06 |
| Sales/Fixed Asset(x) | 1.36 | 1.32 | 1.22 | 1.14 | 1.73 |
| Working Capital/Sales(x) | 2.48 | 2.56 | 3.36 | 4.01 | 5.56 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.73 | 0.76 | 0.82 | 0.88 | 0.58 |
| Receivable days | 13.13 | 12.27 | 12.15 | 14.14 | 13.30 |
| Inventory Days | 5.28 | 5.45 | 5.83 | 7.81 | 8.31 |
| Payable days | 118.67 | 134.04 | 138.53 | 123.86 | 105.92 |
| Valuation Parameters | |||||
| PER(x) | 43.61 | 21.26 | 52.80 | 63.80 | 63.02 |
| PCE(x) | 32.78 | 32.66 | 37.34 | 38.95 | 47.40 |
| Price/Book(x) | 9.01 | 9.79 | 10.50 | 9.48 | 15.06 |
| Yield(%) | 1.56 | 0.97 | 1.06 | 0.66 | 0.46 |
| EV/Net Sales(x) | 7.64 | 8.08 | 8.15 | 7.34 | 10.28 |
| EV/Core EBITDA(x) | 23.88 | 25.19 | 26.74 | 27.86 | 34.99 |
| EV/EBIT(x) | 30.50 | 30.72 | 33.92 | 38.83 | 42.48 |
| EV/CE(x) | 8.41 | 9.15 | 9.39 | 7.78 | 11.62 |
| M Cap / Sales | 7.97 | 8.42 | 8.48 | 7.56 | 10.41 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.25 | 10.54 | 10.40 | -3.38 | 32.01 |
| Core EBITDA Growth(%) | 12.01 | 16.31 | 27.63 | -13.32 | 25.77 |
| EBIT Growth(%) | 6.92 | 21.00 | 40.24 | -24.51 | 23.09 |
| PAT Growth(%) | 3.56 | 35.87 | 50.28 | -31.18 | 18.15 |
| EPS Growth(%) | -48.30 | 35.99 | 49.58 | -30.75 | 18.25 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | 0.05 | 0.15 | 0.24 |
| Current Ratio(x) | 3.48 | 3.39 | 2.43 | 2.07 | 1.75 |
| Quick Ratio(x) | 3.38 | 3.30 | 2.35 | 2.00 | 1.65 |
| Interest Cover(x) | 30.35 | 29.01 | 18.22 | 10.16 | 16.74 |
| Total Debt/Mcap(x) | - | - | - | 0.02 | 0.02 |
Compare Financial Ratios of peers of DR LAL PATHLABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DR LAL PATHLABS | ₹29,064.4 Cr | 2.3% | 6.4% | 21.1% | Stock Analytics | |
| APOLLO HOSPITALS ENTERPRISE | ₹127,771.0 Cr | 1% | 5.5% | 17.6% | Stock Analytics | |
| MAX HEALTHCARE INSTITUTE | ₹106,929.0 Cr | 0.1% | 7.1% | -15.9% | Stock Analytics | |
| FORTIS HEALTHCARE | ₹72,736.4 Cr | 2.6% | -0.4% | 22.7% | Stock Analytics | |
| ASTER DM HEALTHCARE | ₹70,731.9 Cr | 2.3% | 4.7% | 30.8% | Stock Analytics | |
| NARAYANA HRUDAYALAYA | ₹41,493.4 Cr | 2.5% | 8.9% | 2.2% | Stock Analytics | |
DR LAL PATHLABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR LAL PATHLABS | 2.3% |
6.4% |
21.1% |
| SENSEX | 0.6% |
1.2% |
-7.8% |
You may also like the below Video Courses
